专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08603476B2 Humanized anti-human α9-integrin antibody 有权
标题翻译：人源化抗人α9整联蛋白抗体
公开(公告)号：US08603476B2
公开(公告)日：2013-12-10
申请号：US12812341
申请日：2009-01-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
IPC分类号： A61K39/395
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译：本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即包含重链可变区的人源化抗人α9整联蛋白抗体，其包含的SEQ ID NO：11所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体包含由由SEQ ID NO：13所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体由SEQ ID NO：15所示的氨基酸序列和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及预防或治疗涉及人类α9整联蛋白在发病机制中使用抗体。

2. 外观设计

USD669534S1 Electronic whiteboard 有权
公开(公告)号：USD669534S1
公开(公告)日：2012-10-23
申请号：US29416907
申请日：2012-03-28
申请人： Toshihiro Nakashima
设计人： Toshihiro Nakashima

3. 发明申请

US20110117602A1 HUMAN ANTIBODY CAPABLE OF INDUCING APOPTOSIS 审中-公开
标题翻译：人类抗体可诱导疫苗
公开(公告)号：US20110117602A1
公开(公告)日：2011-05-19
申请号：US12743739
申请日：2008-11-18
申请人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
发明人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
IPC分类号： C07K16/30 , C07H21/04 , C12N15/63 , C12P21/00
CPC分类号： C07K16/005 , C07K16/2833 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , G01N33/57484
摘要： A human antibody that has a specific reactivity with multiple tumor cell lines including ATL cells and possesses both safety and therapeutic efficacy and a fragment of said antibody are provided. A human antibody and a fragment of said antibody that may recognize HLA-DR β chain expressed on the surface of tumor cells were obtained. In particular, it was found that a dimer of scFv (diabody) of said antibody may induce potent apoptosis in cells expressing the HLA-DR β chain. The antibody and a fragment of said antibody obtained in accordance with the present invention are useful for a detection reagent, a diagnostic and a medicament for protection or treatment of cancers including ATL and/or viral infectious diseases.
摘要翻译：提供了与多种肿瘤细胞系（包括ATL细胞）具有特异性反应性并具有安全性和治疗功效以及所述抗体片段的人类抗体。可以识别HLA-DR和bgr的人抗体和所述抗体的片段; 获得在肿瘤细胞表面表达的链。特别地，发现所述抗体的scFv（双抗体）的二聚体可能在表达HLA-DR和bgr的细胞中诱导有效的凋亡; 链。根据本发明获得的抗体和所述抗体的片段可用于检测试剂，诊断剂和用于保护或治疗包括ATL和/或病毒感染性疾病的癌症的药物。

4. 发明申请

US20090053212A1 HUMANIZED ANTI-HUMAN OSTEOPONTIN ANTIBODY 失效
标题翻译：人类抗人类骨质疏松症抗体
公开(公告)号：US20090053212A1
公开(公告)日：2009-02-26
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , C12N15/64 , A61P37/06 , C12N1/21 , C12P21/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译：本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体抗人骨桥蛋白抗体。

5. 外观设计

USD575764S1 Intercom 有权
标题翻译：对讲机
公开(公告)号：USD575764S1
公开(公告)日：2008-08-26
申请号：US29297589
申请日：2007-11-14
申请人： Toshihiro Nakashima
设计人： Toshihiro Nakashima

6. 发明授权

US07384633B2 Human type antihuman IgE receptor antibody and fragment 失效
标题翻译：人类抗人IgE受体抗体和片段
公开(公告)号：US07384633B2
公开(公告)日：2008-06-10
申请号：US10484206
申请日：2002-07-18
申请人： Kazuhisa Sugimura , Toshihiro Nakashima , Masaharu Torikai
发明人： Kazuhisa Sugimura , Toshihiro Nakashima , Masaharu Torikai
IPC分类号： A61K39/395
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/21 , C07K2317/622 , Y10S424/805
摘要： An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having high affinity to Fc portion of IgE was obtained using phage antibody display technique. The human anti-IgE receptor antibody and a fragment thereof of the invention has an activity to inhibit the binding between IgE and IgE receptor and hence is expected to be useful as a medicament for treating allergic diseases caused by the binding between IgE and IgE receptor.
摘要翻译：提供抗体或抗体片段，其对于治疗涉及IgE的过敏性疾病是有效的。使用噬菌体抗体展示技术，获得对IgE的Fc部分具有高亲和力的受体（FcepsilonRI）的人抗体及其片段。本发明的人抗IgE受体抗体及其片段具有抑制IgE和IgE受体之间结合的活性，因此预期可用作治疗由IgE和IgE受体结合引起的过敏性疾病的药物。

7. 发明申请

US20080131422A1 Human Anti-Amyloid Beta Peptide Antibody And Fragment Of Said Antibody 失效
标题翻译：所述抗体的人抗淀粉样蛋白β肽抗体和片段
公开(公告)号：US20080131422A1
公开(公告)日：2008-06-05
申请号：US11579072
申请日：2005-04-21
申请人： Kazuhisa Sugimura , Toshihiro Nakashima
发明人： Kazuhisa Sugimura , Toshihiro Nakashima
IPC分类号： A61K39/00 , C07K16/00 , C07H21/04 , C12N15/00 , A61P43/00 , C12N5/00 , C12P21/04 , G01N33/53
CPC分类号： G01N33/6896 , A61K31/7088 , A61K48/00 , C07K16/18 , C07K2317/21 , C07K2317/622 , G01N2333/4709 , G01N2800/2821
摘要： A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody, strongly reacts with Aβ to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.
摘要翻译：提供了与Abeta结合从而抑制Abeta分子聚集的人抗淀粉样蛋白β肽（以下称为“Abeta”）抗体和所述抗体的片段。包含人源抗Abeta抗体的可变区的本发明的抗体及其片段与Abeta强烈反应从而抑制其聚集，因此可用作预防和治疗阿尔茨海默病的药物痴呆。

8. 发明授权

US5946962A Method for manufacturing a turbine shell 失效
标题翻译：涡轮壳体的制造方法
公开(公告)号：US5946962A
公开(公告)日：1999-09-07
申请号：US136422
申请日：1998-08-20
申请人： Toshikazu Fukuda , Toshihiro Nakashima
发明人： Toshikazu Fukuda , Toshihiro Nakashima
IPC分类号： B21D53/78 , B21D53/84 , B23P15/00 , F16H41/28 , B21D28/30
CPC分类号： F16H41/28 , B21D53/78 , B21D53/84 , B23P15/00 , Y10T29/4933
摘要： According to the present invention, a turbine shell is manufactured by a method which includes the steps of preparing a planar blank, simultaneously forming a plurality of blade fixture slits 32A, 32B and 32C in the blank 40, and deforming the blank 40 into a curved concave shape by effecting drawing work.
摘要翻译：根据本发明，通过一种方法制造涡轮壳体，该方法包括以下步骤：制备平面坯料，同时在坯料40中形成多个刀片固定缝32A，32B和32C，并将坯料40变形成弯曲通过进行绘图工作，形成凹形。

9. 发明授权

US5623602A Data transmission confirmation by sending frame with command to change transmitter's resend counter when receiver's buffer is full 失效
标题翻译：通过发送帧的数据传输确认，当接收机的缓冲区已满时，用命令改变发射机的重发计数器
公开(公告)号：US5623602A
公开(公告)日：1997-04-22
申请号：US44485
申请日：1993-04-09
申请人： Toshihiro Nakashima
发明人： Toshihiro Nakashima
IPC分类号： G06F13/00 , H04L12/28 , H04L29/06 , H04L29/08 , G06F13/12 , G06F13/42
CPC分类号： H04L47/10 , H04L29/06 , H04L47/32 , H04L69/324
摘要： A computer network system includes a plurality of computers and a network connected to the computers for allowing them to interchange data. Each computer has a data send module and a data receive module. The data send module is made up of a means for sending a data frame to the network in response to a send request, a resend number storing means for storing the number of times that the data frame is to be resent, and a means for updating the content of the resend number storing means upon receiving a frame for changing the number of times that the data frame is to be resent from the network. The data receive module includes a receive buffer for storing the data frame received from the network, and a means for sending, when the receive buffer is full, the frame for changing the number of times that the data frame is to be resent to the network.
摘要翻译：计算机网络系统包括多个计算机和连接到计算机以允许它们互换数据的网络。每台计算机都有一个数据发送模块和一个数据接收模块。数据发送模块由用于响应于发送请求向网络发送数据帧的装置，用于存储要重发数据帧的次数的重发数量存储装置和用于更新的装置在接收到用于改变要从网络重新发送数据帧的次数的帧时，重发数存储装置的内容。数据接收模块包括用于存储从网络接收的数据帧的接收缓冲器，以及用于当接收缓冲器满时发送用于将数据帧重新发送到网络的次数发送的帧的装置。

10. 发明授权

US09873730B2 Method for improving antibody 有权
公开(公告)号：US09873730B2
公开(公告)日：2018-01-23
申请号：US11815838
申请日：2006-02-07
申请人： Masaharu Torikai , Toshihiro Nakashima
发明人： Masaharu Torikai , Toshihiro Nakashima
IPC分类号： C07K16/00 , C07K16/12 , C07K16/28
CPC分类号： C07K16/00 , C07K16/1271 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/567 , C07K2317/94
摘要： The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式